ADC Therapeutics Reports Third-Quarter 2026 Results, Operational Updates
ADC Therapeutics reported $21 million in third-quarter net product revenue and $189.2 million in cash and cash equivalents as of September 30, 2026. The company said a financial restructuring extends its expected cash runway.
Story updates
12:31:17 PM UTC
SquawkNews
Q3 net product revenue was $21.0M versus $15.8M in Q3 2025; net loss was $25.3M versus $41.0M. The company reported $189.2M in cash at September 30 and said its expected cash runway extends into 2029 after an October restructuring.Material DetailsContext by AI AnalystThis is a quarterly financial u…
Third quarter 2026 net product revenue of $21 million; cash and cash equivalents of $189.2 million as of September 30, 2026Strategic financial restructuring strengthens balance sheet, extending expected cash runway into 2029Abstracts accepted for presentation at ASH 2026, highlighting ZYNLONTA's po…